DiFusion Technologies, Inc.
Georgetown, TX 78626 USA
Research Sector Medical Devices & Tech
Summary Description Self-sterilizing osteoconductive polymer which resists infection and biofilm adhesion.Management Derrick Johns, President ‚???? CEO and Founder: Has a decade of experience in the orthopedic industry and has launched over a dozen products totaling more than $500 million in annual sales. Mr. Johns has directed development teams at Medtronic, Biomet, and Abbott Spine. He has extensive experience in product development, marketing and sales. Most recently Mr. Johns managed Thoracolumbar Business Unit ($50 million) at Abbott Spine and oversaw the Sequoia Project, bringing the entire project to market in only 13 months. Sequoia is the largest and most successful product launch Abbott Spine‚????s history and consisted of a team of 20 individuals in manufacturing engineering, research and development, regulatory, quality engineering, sales and marketing. Abbott Spine was subsequently acquired by Zimmer shortly after the launch of the Sequoia System. Mr. Johns attended Hamilton College and authored a Senior Thesis Natural Selection and Viral Evolution - 1995, after completing a four year enlistment in the US Marine Corps. Mr. Johns served both in the Presidential Honor Guard in Washington D.C. and as a Squad Leader with the 13th Marine Expeditionary Unit-Special Operations Capable MEU-SOC in Operation(s) Desert Shield, Desert Storm and Desert Sting. John Gohde, Executive VP: Mr. Gohde has a decade of experience in the medical device industry managing franchises ranging from $30 million to over $100 million in annual sales at companies including ConMed‚??źLinvatec, Abbott Spine and C.R. Bard. Mr. Gohde has led multiple product development teams and managed a variety of OEM, distributor and supplier relationships. Mr. Gohde has launched multiple products into new and existing markets and has extensive experience in product and platform development, brand management, marketing and sales. Mr. Gohde received his B.S. from Indiana University. He also earned an M.B.A as well as a Masters Degree in Pharmacology with highest honors simultaneously from Loyola. Jami Hafiz, MS PhD, Director of Development: Dr. Hafiz has 10 years of experience in the study of scientific coatings and surface modifications. Most recently he led the Combination Technology Group at Minneapolis-based Chameleon Scientific. Here, Dr. Hafiz led complex product development efforts focused on silver antimicrobial coatings for implantable devices. His responsibilities included technical feasibility assessment, design of effective technology roadmaps, cost analysis, project scheduling, resource allocation and personnel management. He was involved in the creation of Device Master Records for FDA 510(k) submission and managed studies characterizing the cell and tissue response of implantable devices modified with proprietary technologies. Dr. Hafiz has served as a visiting research fellow at CNRS-Orleans in France and the University of Duisberg-Essen in Germany. As a Post Doctoral Researcher he collaborated with Nitto Denko Technical Corporation to design and scale-up a reaction chamber for synthesizing novel nanocrystalline material. He has written or presented more than 20 scientific papers and conference proceedings and has three patents awaiting approval. Dr. Hafiz received his BS and MS degree from the University of Texas at Austin and PhD from the University of Minnesota‚????all in Mechanical Engineering. He received an NSF fellowship for his doctoral dissertation project on the synthesis, characterization and application of nanostructured coatings. Joe Crudden, PhD MBA, Director of Research: Dr. Crudden is a world leading PhD Physical Chemist. He holds 13 patents in surface chemistry technologies with 8 additional patents pending. He is widely regarded as the leading expert in surface chemistry. As an R&D chemist at AW Chesterton, Groveland, MA, Dr. Crudden worked on the development of thermo set polymer composite systems for industrial maintenance and repair. As a technical service and applications development chemist at WR Grace, Hampshire Chemical and Dow Chemical, he was responsible for developing technical information and applications expertise to support the use of the company??Ļs existing surfactants as well as developing a pipeline of new and innovative surfactant products, some of which were shown to be orders of magnitude safer than existing products. Numerous articles were published globally and several patents were issued both in the US and worldwide. At Agion Technology Corp, Wakefield MA, Dr Crudden, working as a senior scientist, focused on the controlled release of antimicrobial metal ions from thermo set plastic systems for applications such as self sterilizing flooring systems. He was also responsible for the development of antimicrobial metal/acid/surfactant systems with broad applications in disinfection, sterilization and agricultural pesticides for which several patents have been filed. Dr. Crudden received his PhD from UCD, (National University of Ireland), where he carried out research on the structure of electrolyte solutions and on the solubilization/dissolution kinetics of oils by surfactant solutions. He holds an MBA from Suffolk University, Boston.
Click here for Financial Data
Keywords: Infectious Disease, Orthopedics, Surgical Site Infections (SSIs), Spinal Surgery
Updated: Jan. 14, 2015
Business Summary: Based in Austin, Texas, DiFUSION is a medical device company focused on the development and implementation of its proprietary CleanFUZE anti-microbial technology for use in orthoped......view more
Products / Services
The company has been working on an initial project named CleanFUZE. CleanFUZE is a spinal implant infused with antibiotic elements, allowing for sustained release of antibiotic therapeutic properties......view more
Technology / Differentiation
The company's approach is to incorporate antibiotic elements into implants used in orthopedic surgery. The embedded elements approach allows for sustained and controlled release of antibiotic therape...view more
Market / Customers
The company has targeted the $1 billion dollar spinal interbody market and will expand its offering within orthopedics.......view more
The Company Seeks a $12 million dollar A Series for Clinical testing and 2010 launch of its Xiphos Posterior Interbody product line. 2011 revenues projected at $7-10 million...view more